Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review.
Marcela ForgeriniRosa Camila LucchettaGustavo UrbanoTales Rubens de NadaiPatrícia de Carvalho MastroianniPublished in: The pharmacogenomics journal (2020)
Non-variceal upper gastrointestinal bleeding (non-variceal UGIB) is a frequent and severe adverse drug reaction. Idiosyncratic responses due to genetic susceptibility to non-variceal UGIB has been suggested. A systematic review was conducted to assess the association between genetic polymorphisms and non-variceal UGIB. Twenty-one publications and 7134 participants were included. Thirteen studies evaluated genetic polymorphism in patients exposed to non-steroidal anti-inflammatory drugs, low-dose aspirin, and warfarin. Eight studies present at least one methodological problem. Only six studies clearly defined that the outcome evaluated was non-variceal UGIB. Genetic polymorphisms involved in platelet activation and aggregation, angiogenesis, inflammatory process, and drug metabolism were associated with risk of non-variceal UGIB (NOS3, COX-1; COX-2; PLA2G7; GP1BA; GRS; IL1RN; F13A1; CDKN2B-AS1; DPP6; TBXA2R; TNF-alpha; VKORC1; CYP2C9; and AGT). Further well-designed studies are needed (e.g., clear restriction to non-variceal UGIB; proper selection of participants; and adjustment of confounding factors) to provide strong evidence for pharmacogenetic and personalized medicine.
Keyphrases
- anti inflammatory drugs
- low dose
- adverse drug
- case control
- drug induced
- end stage renal disease
- ejection fraction
- rheumatoid arthritis
- newly diagnosed
- genome wide
- atrial fibrillation
- type diabetes
- chronic kidney disease
- cardiovascular disease
- oxidative stress
- gene expression
- high dose
- peritoneal dialysis
- dna methylation
- vascular endothelial growth factor
- direct oral anticoagulants
- patient reported
- electronic health record